Plasminogen Activators and their Potential in Therapy

References

• Bachmann F., Kruithof I. E. K. O. Tissue plasminogen activator: chemical and physiological aspects. Semin. Thromb. Hemost. 1984; 10(1)6
   Google Scholar
• Lijnen H. R., Collen D. Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Semin. Thromb. Hemost. 1982; 8(1)2
   Google Scholar
• Castellino F. J. Recent advances in the chemistry of the fibrinolytic system. Chem. Rev. 1980; 81: 431
   Google Scholar
• Flohé L. Single-chain urokinase-type plasminogen activators: new hopes for clot-specific lysis. Eur. Heart J. 1985; 6: 905
   Google Scholar
• Shafer K. E., Santoro S. A., Sobel B. E., Jaffe A. S. Monitoring activity of fibrinolytic agents. Am. J. Med. 1984; 76: 879
   PubMed Web of Science ®Google Scholar
• Collen D., Lijnen H. R. New approaches to thrombolytic therapy. Arteriosclerosis 1984; 4(6)579
   Google Scholar
• Jaffe A. S., Sobel B. E. Thrombolysis with tissue-type plasminogen activator in acute myocar-dial infarction. JAMA 1986; 255(2)237
   Google Scholar
• Collen D. Tissue-type plasminogen activator therapeutic potential in thrombotic disease states. Drugs 1986; 31: 1
   Google Scholar
• Spann J. F., Sherry S. Coronary thrombolysis for evolving myocardial infarction. Drugs 1984; 28: 465
   Google Scholar
• Van de Werf F. Coronary thrombolysis with tissue-type plasminogen activator: an overview. Eur. Heart J. 1985; 6: 902
   Google Scholar
• Tiefenbrunn A. J., Sobel B. E. Tissue-type plasminogen activator (t-PA): an agent with promise for selective thrombolysis. Int. J. Cardiol. 1985; 7: 82
   Google Scholar
• Castellino F. J. Biochemistry of human plasminogen. Semin. Thromb. Hemost. 1984; 10(1)18
   Google Scholar
• Astrup T. Tissue activators of plasminogen. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1966; 25: 42
   PubMedGoogle Scholar
• TIMI Study Group, Thrombolysis in myocardial infarction (TIMI) trial, special report. N. Engl. J. Med. 1985; 312(15)932
   Google Scholar
• Tennant S. N., Dixon J., Venable T. C, Page H. L., Roach A., Kaiser A. B., Frederiksen R., TacogTie L., Kaplan P., Babu N. S., Anderson E. E., Wooten E., Jennings H. S., Breinig J., Campbell W. B. Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase. Circulation 1984; 69(4)756
   Google Scholar
• de Prost D., Guerot C, Laffay N., Horellou M. H., Samama M. Intra-coronary thrombolysis with streptokinase or lys-plasminogen/urokinase in acute myocardial infarction: effects of re-canalization and blood fibrinolysis. Thromb. Haemost. 1983; 50(4)792
   Google Scholar
• Rijken D. C, Wijngaards G., Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim. Biophys. Acta 1979; 580: 140
   PubMed Web of Science ®Google Scholar
• Rijken D. C., Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J. Biol. Chem. 1981; 256(13)7035
   PubMed Web of Science ®Google Scholar
• Vehar G. A., Kohr W. J., Bennett W. F., Pennica D., Ward C. A., Harkins R. N., Collen D. Characterization studies on human melanoma cell tissue plasminogen activator. Bio/Technology 1984; 2(12)1051
   Google Scholar
• Pennica D., Holmes W. E., Kohr W. J., Harkins R. N., Vehar G. A., Ward C. A., Bennett W. F., Yelverton E., Seeburg P. H., Heyneker H. L., Goeddel D. V., Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in. E. coli, Nature (London) 1983; 301: 214
   PubMed Web of Science ®Google Scholar
• Bányai L., Váradi A., Patthy L. Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator. FEBS Lett. 1983; 163(1)37
   PubMed Web of Science ®Google Scholar
• Kagitani H., Tagawa M., Hatanaka K., Ikari T., Saito A., Bando H., Okada K., Matsuo O. Expression in E. coliof finger-domain lacking tissue-type plasminogen activator with high fibrin affinity. FEBS Lett. 1985; 189(1)145
   PubMed Web of Science ®Google Scholar
• van Zonneveld A.-J., Veerman H., Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc. Natl. Acad. Sci. U.S.A. 1986; 83: 4670
   PubMed Web of Science ®Google Scholar
• Hoylaerts M., Rijken D. C, Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J. Biol. Chem. 1982; 257(6)2912
   PubMed Web of Science ®Google Scholar
• Rijken D. C, Hoylaerts M., Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J. Biol. Chem. 1982; 257(6)2920
   Google Scholar
• Sobel B. E., Gross R. W., Robison A. K. Thrombolysis, clot selectivity, and kinetics. Circulation 1984; 70(2)160
   Google Scholar
• Matsuo O., Rijken D. C, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb. Hae-most. 1981; 45(3)225
   Google Scholar
• Korninger C., Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 1981; 46(2)561
   Google Scholar
• Bergmann S. R., Fox K. A. A., Ter-Pogossian M. M., Sobel B. E., Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 1983; 220: 1181
   PubMedGoogle Scholar
• Korninger C, Stassen J. M., Collen D. Turnover of human extrinsic (tissue-type) activator in rabbits. Thromb. Haemost. 1981; 46: 658
   Google Scholar
• Weimar W., Stibbe J., Van Seven A. J., Billiau A., De Somer P., Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2: 1018
   PubMed Web of Science ®Google Scholar
• Van de Werf F., Ludbrook P. A., Bergmann S. R., Tiefenbrunn A. J., Fox K. A. A., de Geest H., Verstraete M., Collen D., Sobel B. E. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N. Engl. J. Med. 1984; 310(10)609
   PubMed Web of Science ®Google Scholar
• Collen D., Rijken D. C, Van Damme J., Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. Thromb. Haemost 1982; 48: 294
   Google Scholar
• Collen D., Stassen J. M., Marafino B., Jr., Builder S., De Cock F., Ogez J., Tajiri D., Pennica D., Bennett W. F., Salwa J., Hoyng C. F. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J. Pharmacol. Exp. Ther. 1984; 231(1)146
   Google Scholar
• Bounameaux H., Verstraete M., Collen D. Comparative pharmacokinetics of human tissue-type plasminogen activator (t-PA), obtained from cell culture (Bowes melanoma) or by recombinant DNA technology. Thromb. Haemost. 1985; 54(1)61, Abstr. 0357
   Google Scholar
• Van de Werf F., Bergmann S. R., Fox K. A. A., de Geest H., Hoyng C. F., Sobel B. E., Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69(3)605
   PubMed Web of Science ®Google Scholar
• Flameng W., Van de Werf F., Vanhaecke J., Verstraete M., Collen D. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates. J. Clin. Invest. 1985; 75: 84
   Google Scholar
• Collen D., Topol E. J., Tiefenbrunn A. J., Gold H. K., Weisfeldt M. L., Sobel B. E., Leinbach R. C, Brinker J. A., Ludbrook P. A., Yasuda I., Buckley B. H., Robison A. K., Hutter A. M., Spadaro J. J., Grossbard E. B. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984; 70(6)1012
   Google Scholar
• Verstraete M., Bernard R., Bory M., Brower R. W., Collen D., De Bono D. P., Erbel R., Huhmann W., Lennane R. J., Lubsen J., Mathey D., Meyer J., Michels H. R., Rutsch W., Shartl M., Schmidt W., Uebis R., von Essen R. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet
   Google Scholar
• 1985; 1: 842
   Google Scholar
• Williams D. O., Borer J., Braunwald E., Chesebro J. H., Cohen L. S., Dalen J., Dodge H. T., Francis C. K., Knattrud G., Ludbrook P., Markis J. E., Mueller H., Desvigne-Nickens P., Passamani E. R., Powers E. R., Rao A. K., Roberts R., Ross A., Ryan T. J., Sobel B. E., Winniford M., Zaret B. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73(2)338, et al.
   Google Scholar
• Verstraete M., Bleifeld W., Brower R. W., Charbonnier B., Collen D., De Bono D. P., Dunning A. J., Lennane R. J., Lubsen J., Mathey D. G., Michel P. L., Raynaud P., Schofer J., Vahan-Ian A., Vanhaecke J., Van de Kley G. A., Van de Serf F., Von Essen R. Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985; 2: 966
   Google Scholar
• Koren G., Weiss A. T., Hasin Y., Appelbaum D., Welber S., Rozenman Y., Lotan C, Mossed M., Sapoznikov D., Luria M. H., Gotsman M. S. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N. Engl. J. Med. 1985; 313(22)1384
   Google Scholar
• Verstraete M., Bounameaux H., De Cock F., Van de Werf F., Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J. Pharmacol. Exp. Ther. 1985; 235(2)506
   PubMed Web of Science ®Google Scholar
• Tiefenbrunn A. J., Robison A. K., Kurnik P. B., Ludbrook P. A., Sobel B. E. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1985; 71(1)110
   PubMed Web of Science ®Google Scholar
• van Mourik J. A., Lawrence D. A., Loskutoff D. J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J. Biol. Chem. 1984; 259(23)14914
   Google Scholar
• Erickson L. A., Hekman C. M., Loskutoff D. J. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 8710
   PubMedGoogle Scholar
• Hekman C. M., Loskutoff D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 1985; 260(21)11581
   Google Scholar
• Kluft C, Jie A. F. H., Sprengers E. D., Verheijen J. H. Identification of a reversible inhibitor of plasminogen activators in blood plasma. FEBS Lett. 1985; 190(2)315
   Google Scholar
• Lecander I., Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br. J. Haematol. 1986; 62: 221
   PubMed Web of Science ®Google Scholar
• Sprengers E. D., Verheijen J. H., Van Hinsbergh V. W. M., Emeis J. J. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim. Biophys. Acta 1984; 801: 163
   PubMedGoogle Scholar
• Saksela O., Hovi T., Vaheri A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. J. Cell. Physiol. 1985; 122: 125
   PubMed Web of Science ®Google Scholar
• Astedt B., Bladh B., Christensen U., Lecander I. Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates. Scand. J. Clin. Lab. Invest. 1985; 45: 429
   PubMed Web of Science ®Google Scholar
• Pizzo S. V., Fuchs H. E., Doman K. A., Petruska D. B., Berger H., Jr. elease of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis. Arch. Intern. Med. 1986; 146: 188
   Google Scholar
• Wiman B., Chmielewska J. A novel fast inhibitor to tissue plasminogen ctivator in plasma, which may be of great pathophysiological significance. Scand. J. Clin. Lab. Invest 1985; 45(Suppl. 177)43
   Google Scholar
• Nielsen L. S., Andreasen P. A., Grøndahl-Hansen J., Skriver L., Danø K. Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an active form with a lower apparent molecular mass. FEBS Lett. 1986; 196(2)269
   Google Scholar
• Andreasen P. A., Nielsen L. S., Grøndahl-Hansen J., Skriver L., Zeuthen J., Stephens R. W., Daner K. Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J. 1984; 3(1)51
   Google Scholar
• Nielsen L. S., Hansen J. G., Andreasen P. A., Skriver L., Danø K., Zeuthen J. Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. EMBO J. 1983; 2: 115, Specific enzyme inhibition and one-step affinity purification
   PubMedGoogle Scholar
• Ichinose A., Kisiel W., Fujikawa K. Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes. FEBS Lett. 1984; 175(2)412
   PubMed Web of Science ®Google Scholar
• Rijken D. C, Emeis J. J., Gerwig G. J. On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells. Thromb. Haemost. 1985; 54(4)788
   Google Scholar
• Pohl G., Källström M., Bergsdorf N., Wallén P., Jörnvall H. Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. Biochemistry 1984; 23: 3701
   PubMed Web of Science ®Google Scholar
• Zamarron C, Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. J. Biol. Chem. 1984; 259(4)2080
   Google Scholar
• Pohl G., Kaplan L., Einarsson M., Wallén P., Jornvall H. Differences between uterine and melanoma forms of tissue plasminogen activator. FEBS Lett. 1984; 168(1)
   Google Scholar
• Jörnvall H., Phol G., Bergsdorf N., Walién P. Differential proteolysis and evidence for a residue exchange in tissue plasminogen activator suggest possible association between two types of protein microheterogenity. FEBS Lett. 1983; 156(1)47
   Google Scholar
• Holmes W. E., Pennica D., Blaber M., Rey M. W., Guenzler W. A., Steffens G. J., Hey-Neker H. L. Cloning and expression of the gene for pro-urokinase in. Escherichia coli, Bio/Technology 1985; 3(10)923
   Google Scholar
• Husain S. S., Lipinski B., Gurewich V. Isolation of plasminogen activators useful as therapeutic and diagnostic agents (single-chain, high-affinity urokinase), U.S. Patent. 1983; 4(381)346
   Google Scholar
• Husain S. S., Gurewich V., Lipinski B. Purification and partial characterization of a single-chain, high-molecular-weight form of urokinase from human urine. Arch. Biochem. Biophys 1983; 220(1)31
   Google Scholar
• Husain S. S., Lipinski B., Gurewich V. Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite. Proc. Natl. Acad. Sci. U.S.A. 1981; 78(7)4265
   Google Scholar
• Wun T-C, Ossowski L. A proenzyme form of human urokinase. J. Biol. Chem. 1982; 257(12)7262
   Google Scholar
• Nielsen L. S., Hansen J. G., Skriver L., Wilson E. L., Kaltoft K., Zeuthen J., Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chro-matography with monoclonal antibody. Biochemistry 1982; 21: 6410
   PubMedGoogle Scholar
• Bernik M. B., Wijngaards G., Rijken D. C. Production by human tissues in culture of im-munologically distinct, multiple molecular weight forms of plasminogen activators. Ann. N.Y. Acad. Sci. 1981; 370: 592
   PubMedGoogle Scholar
• Nolan C, Hall L. S., Barlow G. H., Tribby I. I. E. Plasminogen activator from human embryonic kidney cell cultures, evidence for a proactivator. Biochim. Biophys. Acta 1977; 496: 384
   PubMedGoogle Scholar
• Gurewich V., Pannel R. Biological properties of recombinant and natural pro-urokinase. Thromb. Haemost. 1985; 54(2)558
   Google Scholar
• Collen D. Biological properties of recombinant and of natural pro-urokinase-reply. Thromb. Haemost. 1985; 54(2)559
   Google Scholar
• Gurewich V., Pannell R., Louie S., Kelley P., Suddith R. L., Greenlee R. Effective and fibrin-specific clot lysis of a zymogen precursor form of urokinase (pro-urokinase. J. Clin. Invest. 1731; 73, 1984
   Google Scholar
• Kohno T., Hopper P., Lillquist J. S., Suddith R. L., Greenlee R., Moir D. T. Kidney plasminogen activator: a precursor form of human urokinase with high fibrin affinity. Bio/Technology 1984; 2(7)628
   Google Scholar
• Gurewich V., Pannell R., Greenlee R., Suddith R. The fibrin specificity of single chain-urokinase (SC-UK) induced proteolysis is not dependent on fibrin binding. Thromb. Haemost. 1983; 70(1)1222, Abstr386
   Google Scholar
• Heyneker H., Holmes W., Rey M., Pennica D., Shepard H. M., Seeburg P., Hayflick J., Ward C, Vehar G., Steffens G., Guenzler W., Oetting F., Flohe L. Functional expression of the human urokinase gene in. Escherichia coli, in Genetics of Industrial Microorganisms, K. Ikeda, T. Beppu. Proc. 4th Int. Symp. Genetics of Industrial Microorganisms, Tokyo 1982; 214, Eds.
   Google Scholar
• Hung P. P. Biological activity of a cloned human gene product, urokinase, in. Genetics of Industrial Microorganisms, K. Ikeda, T. Beppu. Symp. Genetics of Industrial Microorganisms, Kodansha 1982; 209, Proc. 4th Int
   Google Scholar
• Ratzkin B., Lee S. G., Schrenk W. J., Roychoudhury R., Chen M., Hamilton T. A., Hung P. P. Expression in Escherichia coli of biologically active enzyme by a DNA sequence coding for the human plasminogen activator urokinase. Proc. Natl. Acad. Sci. U.S.A. 1981; 78(6)3313
   Google Scholar
• Winkler M. E., Blaber M., Bennett G. L., Holmes W., Vehar G. A. Purification and characterization of recombinant urokinase from. Escherichia coli, Bio/Technology 1985; 3(11)990
   Google Scholar
• Zammaron C, Lijnen H. R., Van Hoef B., Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb. Haemost. 1984; 52(1)19
   Google Scholar
• Lijnen H. R., De Wreede K., Demarsin E., Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. Thromb. Haemost. 1984; 52(1)31, IVVariability in fibrinolytic response of plasma of several mammalian species
   Google Scholar
• Collen D., Stassen J. M., Blaber M., Winkler M., Verstraete M. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. Thromb. Haemost. 1984; 52(1)27, IIIThrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis
   Google Scholar
• Collen D., Stump D., Van de Werf F., Jang I. K., Nobuhara M., Lijnen H. R. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase. Circulation 1985; 72(2)384
   Google Scholar
• Van de Werf F., Nobuhara M., Collen D. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Ann. Intern. Med. 1986; 104(3)345
   Google Scholar
• Van de Werf F., Vanhaecke J., de Geest H., Verstraete M., Collen D. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 74(5)1066
   Google Scholar
• Collen D., Zamarron C, Lijnen H. R., Hoylaerts M. Activation of plasminogen by pro-urokinase. J. Biol. Chem. 1986; 261(3)1259, IIKinetics
   Google Scholar
• Lijnen H. R., Zamarron C, Blaber M., Winkler M. E., Collen D. Activation of plasminogen by pro-urokinase. J. Biol. Chem. 1986; 261(3)1253, IMechanism
   Google Scholar
• Sumi H., Toki N., Sasaki K., Mihara H. Comparative properties of single and double poly-peptide chains of high molecular weight urokinase, in, J. F. Davidson, F. Bachmann, C. A. Bouvier, E. K. O. Kruithof. Churchill Livingstone, Edinburgh 1983; Vol. 6: 165, Progress in Fibrinolysis
   Google Scholar
• Stump D. C, Thienpont M., Collen D. Utokinase-related proteins in human urine. J. Biol. Chem. 1986; 261(3)1267
   Google Scholar
• Stump D. C, Lijnen H. R., Collen D. Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. J. Biol. Chem. 1986; 261(3)1274
   Google Scholar
• Kasai S., Arimura H., Nishida M., Suyama T. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J. Biol. Chem. 1985; 260(22)12377
   PubMed Web of Science ®Google Scholar
• Kasai S., Arimura H., Nishida M., Suyama T. Primary structure of single-chain pro-urokinase. J. Biol. Chem. 1985; 260(22)12382
   Google Scholar
• Kasai S., Arimura H., Nishida M., Suyama T. Thrombolytic properties of an inactive proen-zyme form of human urokinase secreted from human kidney cells. Cell Struct. Func 1985; 10: 151
   Google Scholar
• Wijngaards G., Los P., van Wezel A. L., Van Der Velden C. A. M., Groeneveld E. Fibrin binding properties of different forms of preurokinase isolated from a monkey kidney cell culture. Thromb. Haemost. 1983; 50(1)1015, Abstr,:320
   Google Scholar
• Riccio A., Grimaldi G., Verde P., Sebastio G., Boast S., Blasi F. The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res. 1985; 13(8)2759
   Google Scholar
• Hollander I. J., Gurewich V. Identification of a 65,000 dalton plasminogen activator in urine and human kidney cell culture medium, in. Progress in Fibrinolysis, J. F. Davidson, F. Bachmann, C. A. Bouvier, E. K. O. Kruithoff. Churchill Livingstone, Edinburgh 1983; Vol. 6: 174
   Google Scholar
• Hayashi S., Yamada K. Purification and properties of fibrin high-affinity urokinase from human urine. Thromb. Haemost. 1985; 54(1)Abstr. P602, 102
   Google Scholar
• Husain S. S. Requirement of Zn for a binding interaction between urokinase-type plasminogen activator and fibrin. Thromb. Haemost. 1985; 54(1)122, Abstr. 0724
   Google Scholar
• Husain S. S. Modulation of urokinase-catalyzed plasminogen activation by. Thromb. Haemost. 1985; 54(1)122, Abstr. 0725 Zn
   Google Scholar
• Wun T-C, Schleuning W-D. Isolation and characterization of urokinase from human plasma. J. Biol. Chem. 1982; 257(6)3276
   Google Scholar
• Takasugi S., Nishiki M., Okumichi T., Kanao M., Ezaki H. Isolation of urokinase, proen-zyme of urokinase and tissue-type plasminogen activator from human plasma by combination of two kinds of affinity column chromatography methods, Hiroshima. J. Med. Sci. 1984; 33(3)563
   Google Scholar
• Wun T-C., Capuano A. Spontaneous fibrinolysis in whole human plasma. J. Biol. Chem. 1985; 260(8)5061
   Google Scholar
• Vassalli J-D., Baccino D., Belin D. A cellular binding site for the MR 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 1985; 100: 86
   PubMed Web of Science ®Google Scholar
• Stoppelli M. P., Corti A., Soffientini A., Cassani G., Blasi F., Assoian R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 4939
   PubMedGoogle Scholar
• Bajpai A., Baker J. B. Urokinase binding sites on human foreskin cells. Biochem. Biophys. Res. Commun. 1985; 133(3)994, Evidence for occupancy with endogenous urokinase
   Google Scholar
• Gurewich V., Pannell R. Clot lysis by pro-urokinase (PUK) and/or t-Pa—a comparative study. Thromb. Haemost. 1985; 54(1)122, Abstr. 0722
   Google Scholar
• Collen D., Stassen J.-M., Stump D. C, Verstraete M. Synergism of thrombolytic agents in vivo. Circulation 1986; 74(4)838
   Google Scholar
• Collen D., Stump D. C, Van de Werf F. Coronary thrombolysis in patients with acute my-ocardial infarction by intravenous infusion of synergic thrombolytic agents. Am. Heart J. 1986; 112(5)1084
   Google Scholar
• Dupe R. J., Green J., Smith R. A. G. Acylated derivatives of streptokinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. Thromb. Haemost. 1985; 51(1)56
   Google Scholar
• Kasper W., Meinertz T., Just H. Fibrinolytic efficacy of a new acylated streptokinase-plasminogen activator complex (BRL 26921) in patients with acute myocardial infarction: comparison between intravenous and intracoronary administration. Thromb. Haemost. 1985; 54(1)1258, (Abstr. P213)
   Google Scholar
• Bode C, Matsueda G. R., Hui K. Y., Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science 1985; 229: 765
   PubMed Web of Science ®Google Scholar
• Baughman K. L., Maroko P. R., Vatner S. F. Effects of coronary artery reperfusion on myocardial infarct size and survival in conscious dogs. Circulation 1981; 63: 317
   PubMedGoogle Scholar
• Verstraete M. Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarction. Eur. Heart J. 1985; 6: 586
   Google Scholar
• Topol E. J., Bell W. R., Weisfeldt M. L. Coronary thrombolysis with recombinant tissue-type plasminogen activator. Ann. Intern. Med. 1985; 103(6)837
   Google Scholar
• O'Neill W., Timmis G. C., Bourdillon P. D., Lai P., Ganghadarhan V., Walton J., Jr., Ramos R., Laufer N., Gordon S., Schork M. A., Pitt B. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N. Engl. J. Med. 1986; 314(13)812
   PubMed Web of Science ®Google Scholar
• Topol E. J., Weiss J. L., Brinker J. A., Brin K. P., Gottlieb S. O., Becker L. C, Bulkley B. H., Chandra N., Flaherty J. T., Gerstenblith G., Gottlieb S. H., Guerci A. D., Ouyang P., Llewellyn M. P., Weisfeldt M. L., Shapiro E. P. Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of coronary angioplasty. J. Am. Coll. Cardiol. 1985; 6(2)426
   Google Scholar
• Graor R. A., Risius B., Young J. R., Denny K., Beven E. G., Geisinger M. A., Hertzer N. R., Krajewski L. P., Lucas F. V., O'Hara P. J., Ruschhaupt W. F., Winton S., Zelch M. G., Grossbard E. B. Peripheral artery and bypass graft thrombolysis with recombinant human tissue-type plasminogen activator. J. Vasc. Surg. 1986; 3: 115
   Google Scholar
• Jay R. M., Turpie A. G. G., Carter C. J., Hirsh J. Systemic fibrinolysis in venous thrombosis patients treated with recombinant tissue-type plasminogen activator. Thromb. Haemost. 1985; 54(1)Abstr. 01031, 174
   Google Scholar
• Bounameaux H., Vermylen J., Collen D. Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. Ann. Intern. Med. 1985; 103(1)64
   PubMed Web of Science ®Google Scholar
• Zivin J. A., Fisher M., DeGirolami U., Hemenway C. C, Stashak J. A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230: 1289
   PubMed Web of Science ®Google Scholar
• Fox K. A. A., Robison A. K., Knabb R. M., Rosamond T. L., Sobel B. E., Bergmann S. R. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 1985; 72(6)1346
   PubMedGoogle Scholar
• Gold H. K., Leinbach R. C, Garabedian H. D., Yasuda T., Johns J. A., Grossbard E. B., Palacios I., Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73(2)347
   Google Scholar
• Sobel B. E., Fields L. E., Robison A. K., Fox K. A. A., Sarnoff S. T. Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator. Proc. Natl. Acad. Sci. U.S.A. 1985; 82: 4258
   Google Scholar
• Sasaki K., Moriyama S., Tanaka Y., Sumi H., Toki N., Robbins K. C. The transport of 125labeled human high molecular urokinase across the intestinal tract in a dog model with stimulation of synthesis andJor release of plasminogen activators. Blood 1985; 66(1)69
   Google Scholar
• Toki N., Sumi H., Sasaki K., Boresiha I., Robbins K. C. Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins. J. Clin. 1985; 75: 1212
   Google Scholar